Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Tradingview

Published November 16, 2026

Helus Pharma's psychedelic depression drug succeeds in late-stage study - TradingView

Read the full story at Tradingview

Helus Pharma NEO:HELP said on Monday its experimental psychedelic drug showed statistically significant improvement in depression symptoms.

Surfaced by 4 Google Alerts

  • Psychedelics
  • Magic mushrooms
  • Psychedelic biotech
  • Ketamine